|
|
||
|
|
United States Patent: 5,980,944 Inventors: Stevens; Charles A. (Lansdale, PA); Hoy; Michael R. (North Wales, PA); Roche; Edward J. (Paoli, PA)Assignee: McNeil-PPC, Inc. (Skillman, NJ) Appl. No.: 978358Filed: November 25, 1997 A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a pharmaceutical suitable for the treatment of gastric disorders selected from the group consisting of granules of diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof; and a therapeutically effective amount of simethicone wherein the pharmaceutical and simethicone are separated by a barrier coat on the granules which is substantially impermeable to simethicone. SUMMARY OF THE INVENTION In accordance with the present invention, we have
discovered a solid oral dosage form for the treatment of gastrointestinal
disorders comprising a therapeutically effective amount of a
pharmaceutical suitable for the treatment of gastric disorders selected
from the group consisting of cimetidine, ranitidine, famotidine,
diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable
salts thereof and combinations thereof; and a therapeutically effective
amount of simethicone wherein the oral dosage form has a first portion
containing the simethicone and a second portion containing the
pharmaceutical suitable for the treatment of gastric disorders wherein the
first and second portions are in contact with and separated by a barrier
which is substantially impermeable to simethicone. Claim 1 of 12 Claims 1. A solid oral dosage form for the treatment of
gastrointestinal distress comprising simethicone and a pharmaceutical
having an enhanced dissolution profile, comprising a therapeutically
effective amount of a pharmaceutical for the treatment of gastric
disorders selected from the group consisting of diphenoxylate, loperamide
and loperamide-N-oxide, pharmaceutically acceptable salts thereof, and
combinations thereof; wherein the pharmaceutical is provided in the form
of coated granules which are coated with a nonenteric polymer coating
impermeable to simethicone; a therapeutically effective amount of
simethicone free of said nonenteric coating; and pharmaceutically
acceptable excipients. ____________________________________________
|
|
|